Methadone use as a second-line agent for severe cancer-related pain is increasing in the field of hospice and palliative care. It has a number of qualities that make its use favorable, including lack of known active metabolites and presumed relative safety from adverse effects such as opioid-induced neurotoxicity (OIN). This article describes a case of a patient undergoing treatment of severe cancer-related pain who developed OIN in the setting of oral methadone use. As the use of methadone increases, more research into its pharmacologic and pharmacokinetic properties will be necessary.
Get full access to this article
View all access options for this article.
References
1.
GazelleG, FinePG: Fast facts and concepts methadone for pain: #75. J Palliat Med, 2004; 7.
BrueraE, SweeneyC: Methadone use in cancer patients with pain: A review. J Palliat Med, 2002; 5:127–138.
4.
RipamontiC, ZeccaE, BrueraE: An update on the clinical use of methadone for cancer pain. Pain, 1997; 70:109–115.
5.
AuretK, GouckeR, IlettK, et al.: Pharmokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. Ther Drug Monit, 2006; 28.
6.
TwycrossR, WilcockA: Hospice and Palliative Care Formulary USA, 2nd ed. Palliativedrugs.com Ltd., 2008, pp. 319–323.
7.
MercadanteS: Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain, 1998; 74:5–9.
8.
MatzoM, DawsonK: Opioid-induced neurotoxicity: An overview of symptoms and recommendations for management. Am J Nurs, 2013; 113.
9.
SarhillN, DavisMP, WalshD, NounehC: Methadone-induced myoclonus in advanced cancer. Am J Hosp Palliat Care, 2001; 18:51–53.
10.
ViganoA, FanD, BrueraE: Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain, 1996; 67:115–119.
11.
SmithMT: Neuroexcitatory effects of morphine and hydromorphone: Evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol, 2000; 27:524–528.
12.
De StoutzND, BrueraE, Suarez-AlmazorM: Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage, 1995; 10:378–384.
13.
TeutebergWG: Fast facts and concepts opioid-induced hyperalgesia #142. J Palliat Med, 2010; 13:1486–1487.
14.
MercadanteS: Dantrolene treatment of opioid-induced myoclonus. Anesth Analg, 1995; 81:1307–1308.
15.
DarbinO, RissoJJ, RostainJC: High pressure enhanced NMDA activity in the striatum and the globus pallidus: Relationships with myoclonia and locomotor and motor activity in rat. Brain Res, 2000; 852:62–67.
16.
DzoljicMR, Poel-HeisterkAL: Delta opiate receptors are involved in the endopioid-induced myoclonic contractions. Brain Res Bull, 2008; 8:1–6.
17.
BartlettSE, CramondT, SmithMT: The excitatory effects of morphine-3-glucoronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. Life Sci, 1994; 54:687–694.
18.
ChenL, HuangLM: Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by mu opioid. Neuron, 1991; 7:319–326.
19.
MercadanteS, ArcuriE: Hyperalgesia and opioid switching. Am J Hosp Palliat Med, 2005; 22.
20.
WilsonRK, WeissmanDE: Fast facts and concepts neuroexcitatory effects of opioids: Patient assessment #57. J Palliat Med, 2004; 7:579.
21.
WilsonRK, WeissmanDE: Fast facts and concepts neuroexcitatory effects of opioids: Treatment #58. J Palliat Med, 2004; 7:580–581.
